Member Info for LlamaFarmer

Dvh you read tg this morning?

Research with links, charts, pinned messages to make it easy.

10 minute read for all you need.

Operates a no 6xxxxx policy.

H t t p s : / / t. me/+8FD4QMxNcORkYmM0

bones

h t t p s ://****/+8fd4qmxncorkymm0

Bones - ??

He's a completely useless ramper isn't he :)

It is better to have a share price that goes up, retraces a little then goes up again and retraces a little, we all know that is the way to avoid a pump and dump.

The thing I like about Solvonis and the reason why i've crawled out from under my rock with this is, I don't think anyone is going to get hurt.

SVN001 is going to get licensed Q4 or before - that's what the CEO has told us, they've not missed any other deadlines so i'm taking that as read.

SVN002 Phase 2b with a 502b pathway, we are told the FDA are supportive - we can look at the RNS info to check and agree this, the FDA have advised them to create a bridge between Spravato's Esketamine data and Solvonis Esketamin data, they have immediately set that in motion.

SVN014 - Three lead candidates to choose from - it keeps on getting better.

What will be unusual is when the RNS lands, Solvonis Therapeutics are please to announce the licensing of SVN001 to XXXXX for the sum of £ XXXXXX

The share price hasn't really reacted yet, people are focusing on 0.4p as being a target to breach.

When that RNS lands the market will realise this is a domino move, the one where the Queen leapfrogs over the board taking the other pieces and clears it!

SVN001 license opens the NHS and Europe, leads to SVN002 being listed on the Nasdaq leads to SVN014 also being listed on the Nasdaq.

The next days opening share price will not be 0.4p, it will be a complete bun fight.

Still value to be had down here imo.

Google it, there are vids on how to join up.

Join Telegram

Remove the spaces.

H t t p s:/ /t . me/+8FD4QMxNcORkYmM0

H t t p s:/ /t . me/+8FD4QMxNcORkYmM0

Much calmer

More informed

Analyst data

Or this complete rubbish on lse?

Find the @ askcharles group.

Tricky,

There are a few of us with decent sized holdings here from 0.10 GPL days and onwards, the 0.13p placing was the water shed moment to buy more and get ready to hold them for a decent ride upwards.

It is a shame you can't get Telegram to work as i'd like to have a chat with you.

If Solvonis was sold for £1b, £500m, £250m, £125m

£1b / 6.240 Billion shares = 16p a share

£500m = 8p a share

£250m = 4p a share - Derisory.

£125m - after you have finished spitting in their face it would still be 2p a share.

Got to understand what we are holding here, is it potential over reality - yes, does that potential have a monetary value - yes it does, it's called a License fee and that deal is being done in Q4 - will leave them fully cashed up for SVN002 and SVN014, they won't be desperate so Dennis Purcell can add to this mountain of Billion dollar Pharma deals that he has written.

People posting 0.4p for a trade pot - good for them short term, mugs in the medium term, longer term they'll have to delete the ticker and not check the share price.

Also re Anthony Tennyson.

Roast interview 1.

"Ohh yeah and we are in talks with six pharmas ...

Roast interview today:

" and in negotiations with a couple of Pharmas "

So they have whittled it down to two parties.

Deal is getting done and the market is still oblivious.

Tricky,

The valuations are no where near what this is going to be worth.

Dennis Purcell is valuing the aud treatments in the hundreds of millions.

Pharma Ventures put a low ball valuation of £60m + 150m back end payments.

Anthony Tennyson is saying look at the GPL drugs took Novo Nordisk from no where to the top pharma in Europe.

Today he has told us they will license svn001 to a partner, they wont sell it, that means a p. e. Value can be worked against the share price but also and more importantly this adds value to the buyout partner.

Someone posted on Telegram, is it J & J ( The owners of Spravato ) or is it Astra Zeneca ( love working with the NHS )

Quite a few pi's have loaded serious amounts of stock here, the ones ive spoken to have the same thought process.

"Wait for the buyout"

DVH,

There is that awful phrase "the dim and desperate".

Best in Class is expected across the whole pipeline, why?

Mainly the BOD

- The science of Nutt, Morgan & Crome

- The Financial accumen on Tennyson, Nelson, Pucell and Neates.

- The unmet needs they are aiming to plug.

They have funded and are promoting correctly the best in class products, the respective governing bodies of the UK and USA recognised them early doors as professional people on a mission to fill the gap in societys largest unmet needs.

Talk of 0.5p or the BOD's options price of 0.73+p is massively undervaluing what they are doing here, they know what this is going to be worth and it isn't fractions of a penny.

"Best in class"

SVN001 - Best in Class - NHS picked it up straight away and supported it!

SVN002 - Expected to be the same, the FDA certainly thinks so with the support they have given it.

SVN014 - While the Company had previously anticipated selecting a single lead candidate at this stage, the positive performance of three candidates has delivered an optimal outcome - a strong, competitive shortlist with multiple best-in-class contenders. This outcome increases optionality, strengthens the dataset and enhances the probability of selecting a best-in-class candidate with strong commercial potential.

There was a long post in the Telegram group this morning ...